SCO-240, a small molecule antagonist for somatostatin receptor type 5 (SSTR5), stimulates growth hormone secretion in humans

Harunobu Nishizaki¹, Tomoya Kagawa¹, Jun Sugama¹, Akihiro Kobayashi¹, Hideki Hirose¹, Shizuo Kasai¹, Tsuyoshi Maekawa¹, Yusuke Moritoh¹, Masanori Watanabe¹


¹SCOHIA PHARMA, Inc., Kanagawa, Japan

The 96th Annual Congress of JES 02–6–12




Somatostatin and Somatostatin Receptors (SSTR1-5)

- Somatostatin (SST, SRIF) is a 14 or 28 amino acid peptide located in brain, pituitary, pancreas, stomach and gut, etc.
- SST suppresses endocrine and exocrine hormone secretion via five G-protein-coupled receptors (GPCRs) coupling with Gi/Go (SSTR1-5)
- The difference of tissue localization of SSTR1-5 defines the physiological function of each SSTR




Hormone o	hanges b	y SSTRs a	activation	
	SSTR1	SSTR2	SSTR3	SSTR
GH		\downarrow		
Glucagon		\downarrow		
Insulin				
GLP-1				
ΡΥΥ				
GIP		\downarrow		
ССК		Ļ		







Accumulated Evidence Indicated That SSTR5 Antagonism May be Therapeutically Effective in Following Diseases




effect activation inhibition


> *Pharmacol Res Perspect. 2023, 11(1):e01043 **ACS Med Chem Lett. 2018, 9(11):1082-1087 ***Endocrinology. 2017, 158(11):3859-3873 ****Neurogastroenterol Motil. 2010, 22(2):204-209



SCO-240 is the Only Clinical Stage Selective SSTR5 Antagonist

- An orally available small molecule
- Human SSTR5 IC₅₀: 2.0 nmol/L
- Highly selective to SSTR5 among SSTR1-5






Antagonist activity (cyclic AMP assay) Cell:

Chinese hamster ovary (CHO) cells stably expressing human SSTR5 **Treatment:**

The cells were stimulated with 0.1 nM SST-28 and 0.5 µM forskolin w/wo various concentrations of SCO-240.



Means + SD (quadruplicate)

Selectivity (competitive radioligand binding assay) Material:

The membrane fraction of CHO-K1 cells expressing each human SSTR

Treatment:

The membrane was incubated with 1 µM SCO-240 and [125]]SST-14.







SCO-240 Phase 1 Single Ascending Dose Study Study design

A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SCO-240 in Healthy Adult **Subjects**

Primary Objective

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics after a single oral dose of SCO-240 in healthy adult subjects in a randomized, double-blind, placebo-controlled, comparative study 40mg






80mg

Racial difference effect part: Cohort 4a, 4b



SCO-240 Phase 1 Single Ascending Dose Study Excellent pharmacokinetic profiles allowing once-daily oral dosing in humans



			AUC _(0-inf) (ng∙hr/mL)	C _{max} (ng/mL)	T _{max} (hr)	T _{1/2} (hr)
Dose ascending part	Japanese	1 mg (N=6)	990.1	69.6	3.5	10.2
		3 mg (N=5)	3176.8	220.6	3.0	10.7
		10 mg (N=6)	10240.9	696.7	4.0	11.0
		20 mg (N=6)	17477.8	1144.2	3.0	12.2
		40 mg (N=6)	22033.5	1436.5	4.0	11.4
		80 mg (N=6)	38187.2	2351.7	4.0	12.6
		160 mg (N=6)	51622.8	3820.0	3.0	11.7
Racial difference effect part	Caucasian	20 mg (N=6)	13790.1	873.5	3.0	11.9
Food effect part	Pre-breakfast	20 mg (N=12)	8084.1	519.3	2.3	11.3
	Post-breakfast	20 mg (N=12)	10831.3	517.3	10.0	10.7



SCO-240 Phase 1 Single Ascending Dose Study Safe and well tolerated in single doses

	Dose Ascending Part							Racial Difference Effect Part				
	Placebo	1 mg	3 mg	10 mg	20 mg	40 mg	80 mg	160 mg	Total	Placebo	20 mg	Total
N	14	6	6	6	6	6	6	6	56	2	6	8
TEAEs	0 (0.0)	2 (33.3)	1 (16.7)	0 (0.0)	1 (16.7)	2 (33.3)	1 (16.7)	0 (0.0)	7 (12.5)	1 (50.0)	0 (0.0)	1 (12.5)
Abdominal discomfort	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal pain lower	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Tonsillitis	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Blood corticotrophin increased	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)
Blood triglycerides increased	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)	1 (16.7)	1 (16.7)	0 (0.0)	4 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	1 (12.5)
Hypoaesthesia	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)

Number of Subjects (%)

TEAE: Treatment-Emergent Adverse Events

TEAEs related to the Drug



No serious adverse events were observed, and all TEAEs were mild in intensity.



SCO-240 Phase 1 Single Ascending Dose Study GLP-1, insulin, and gallbladder contraction were unchanged

--- Placebo

1 mg

3 ma

10 mg


🕶 20 ma

🔶 40 ma

→ 80 mg

🕂 160 mg

12



GLP-1

Time after administraion (hr)

Meal


15-

10

-2

Ω

pmol/L



These parameters, regulated by SSTR5 in mice, were unexpectedly unchanged in humans
Additional exploratory analyses were conducted to determine the physiological role of SSTR5 in humans

Means + SD (n=14 for placebo group, and 6 for SCO-240 groups)




8

→ Placebo
→ 1 mg
→ 3 mg
→ 10 mg
→ 20 mg
→ 40 mg
→ 80 mg
→ 160 mg


→ Placebo
→ 1 mg
→ 3 mg
→ 10 mg
→ 20 mg
→ 40 mg
→ 80 mg
→ 160 mg

Somatostatin Negatively Regulates Growth Hormone Secretion from Somatotroph in the Anterior Pituitary

A key SSTR subtype that regulates GH release was largely unknown in humans




Growth hormone is secreted from anterior pituitary somatotrophs in a pulsatile fashion under the control of multiple stimulatory (GHRH, ghrelin) and inhibitory (somatostatin) factors







Additional Analysis in the Phase 1 Study Significant stimulation on GH release and neutral effects on other pituitary hormones in humans




 Increased GH levels by SCO-240 are comparable to those after the injection of therapeutic dose of recombinant human GH GH: growth hormone FSH: follicle-stimulating hormone LH: luteinizing hormone TSH: thyroid-stimulating hormone ACTH: adrenocorticotropic hormone PRL: prolactin

Means + SD (n=14 for placebo group, and 6 for SCO-240 groups) Gray area indicates the normal range for each hormone



Summary



- SCO-240 was safe and well tolerated and exhibited once-daily oral dosing potential
- Robust GH secretion was demonstrated with SCO-240-mediated SSTR5 antagonism in humans
- These results support the further clinical development of SCO-240 as an oral treatment option for GH-related disorders



IGF-1: insulin-like growth factor 1 rhGH: recombinant human GH